QbMobile
DeviceQbMobile is a software application that can be installed on a smartphone device used to measure activity, attention, impulsivity, and movement patterns in participants over a two-day period.
NCT Number: NCT07220330
The purpose of this study is to investigate QbMobile ability to collect and provide accurate and objective data which can be used to facilitate assessment and treatment procedures for ADHD in a clinical setting as well as remotely.
Interested in participating?
Request Info6 year–60 year
All sexes
Observational
Prodigy Psychiatric Group, San Jose, California, United States
This study aims to evaluate the performance of QbMobile in children, adolescents, and adults from the normative population, those referred for an initial ADHD assessment, and individuals with an ADHD diagnosis who are not currently receiving ADHD treatment.
Participants will complete the 10-minute QbMobile test on their personal device during a scheduled clinical visit. They will then repeat the test remotely the following day at the same time as the previous test +/-3 hours.
For participants referred for an ADHD assessment or a has an ADHD diagnosis, QbMobile must be completed prior to initiating any ADHD treatment.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
QbMobile is a software application that can be installed on a smartphone device used to measure activity, attention, impulsivity, and movement patterns in participants over a two-day period.
Time frame: 10-minute testing period
QbMobile generates standardized scores (SD-scores) for attention, impulsivity, activity, and movement patterns using age and sex at birth adjusted norms. These scores provide objective data collected during the 10-minute test session and are automatically included in a standardized report generated immediately upon test completion. This supports evaluation of test validity for ADHD-related symptom measurement.
Time frame: 10 minute testing period
QbMobile Total score (0-100 where 0 indicates a low likelihood of exhibiting ADHD symptoms and 100 indicates a high likelihood of exhibiting ADHD symptoms) will be compared across participants assessed for ADHD, diagnosed but untreated, and normative participants to evaluate differentiation in ADHD symptom likelihood. This score is automatically generated in the QbMobile report upon test completion.
Time frame: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
SD-scores for attention, impulsivity, activity, and movement patterns will be compared between in-clinic and remote QbMobile tests to assess consistency and reliability.
Time frame: QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2).
Exploratory analyses will be conducted on raw QbMobile data collected at Visit 1 and Visit 2 to identify potential additional parameters that may serve as indices of activity, attention, impulsivity, and movement. These parameters will be evaluated for their potential association with ADHD symptomatology.
Qbtech AB
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07037030
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder (ADHD)
Brookline, Massachusetts, United States
View Trial DetailsNCT06792175
Anxiety Disorders, Anxiety, Generalized
Brookline, Massachusetts, United States
View Trial DetailsNCT06604845
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder (ADHD)
Gothenburg, Sweden
View Trial DetailsNCT07566468
ADHD, Anxiety Disorders
Bethesda, Maryland, United States
View Trial Details